Inspira™ Announces Business Plan Goals

The company actively promotes INSPIRA™ ART100, we Following FDA approval, we plan further market expansion and accelerate plans for our breakthrough INSPIRA™ ART (2nd generation).

Ra'anana, Israel, June 20, 2024 /PRNewswire/ — Inspira™ Technologies OXY BHN Ltd. Inspira, Inc. (Nasdaq: IINN), (Nasdaq: IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, today announced that Joe Hyeyoung, President and Co-Founder of the Company, presented a business plan containing goals for the Company's next-generation technology during a conference call today.

Inspira said in a conference call: $19 billion Ventilator Market. Inspira's mission is to eliminate the need for traditional ventilators. Their flagship product, the INSPIRA™ ART (Gen 2) device, is designed to provide direct blood oxygenation while the patient remains awake and without the need for intubation.

The company is working on a 510(k) multi-site rollout in parallel with the continued development of its groundbreaking adaptive blood oxygenation technology, INSPIRA ART (2nd generation). we The Food and Drug Administration (FDA) has approved the INSPIRA ART100 cardiopulmonary support device. The company has already received its first purchase order from Glo-Med Networks, Inc. under an existing distribution agreement with the company. we distributor, with first deliveries scheduled for Q4 2024.

Key highlights from the presentation:

• The company will outline its groundbreaking INSPIRA™ ART (2nd generation) technology and aim to capture projected market share. $19 billion Global mechanical ventilation market size predicted by 2030.
• 2024-2025 Business Objectives: Inspira is on track to submit for FDA approval of its HYLA™ Blood Sensor, a key component of the INSPIRA™ ART (Gen 2) System, and plans to integrate this technology into its next-generation INSPIRA™ ART100 device. Additionally, Inspira is well advanced in Phase 2 research and development of its VORTX™ Blood Delivery System, and Phase 3 verification and validation testing of the HYLA Blood Sensor.
• Inspira is using INSPIRA™ ART100 in multiple We hope to use this technology as a popularization model for the next generation of INSPIRA™ ART (2nd generation) in various locations and countries. Inspira™ ART100's R&D and regulatory success story hints at future potential breakthroughs from INSPIRA.™ ART (2nd generation)

About Inspira Technologies OXY BHN LTD.

Inspira™ Technologies is an innovative medical technology company in the field of life support. The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500, features the company's adaptive blood oxygenation technology, designed to continuously measure a patient's blood parameters in real time and deliver the required amount of oxygen directly to the blood. By increasing a patient's oxygen saturation within minutes, the technology has the potential to keep patients awake during treatment, allowing patients to be treated in and out of the intensive care unit and reducing the need for mechanical ventilation necessitating intubation and medically induced comas.

The company received FDA 510(k) clearance for its INSPIRA ART100 cardiopulmonary bypass system.

Our other products, including INSPIRA ART (2nd generation) and the HYLA™ blood sensor, have not been approved for sale by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.

For more information, please visit our company website: https://inspira-technologies.com

Forward-Looking Statements

This press release contains express or implied forward-looking statements. we Federal securities laws. These forward-looking statements and their implications are based only on the current expectations of our management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, we use forward-looking statements in describing our plans to structure an opportunity to acquire our shares. $19 billion The Company is not obligated to revise or publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. More detailed information regarding the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2023. we Available at the SEC's website at http://www.sec.gov.

For more information:
Public Relations Manager
Adi Shmueli
Inspira Technologies
inquiry
+972-9-9664485

Copyright © 2018-2024 Inspira Technologies OXY BHN LTD., All rights reserved.

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/inspira-announces-business-plan-targets-302178006.html

SOURCE Inspira Technologies